(Q34013705)

30 July 2017

1 reference

title

Sustained-release fampridine for symptomatic treatment of multiple sclerosis (English)

1 reference

30 July 2017

0 references

Anne R Korenke

1

1 reference

30 July 2017

Michael P Rivey

series ordinal

2

1 reference

30 July 2017

Douglas R Allington

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

9 September 2008

1 reference

Annals of Pharmacotherapy

30 July 2017

published in

1 reference

30 July 2017

volume

42

1 reference

30 July 2017

issue

10

1 reference

30 July 2017

page(s)

1458-1465

1 reference

Management of multiple sclerosis

30 July 2017

cites work

1 reference

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

21 January 2018

1 reference

The use of 4-aminopyridine (fampridine) in demyelinating disorders.

21 January 2018

1 reference

Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment

21 January 2018

1 reference

Fampridine-SR for multiple sclerosis and spinal cord injury

21 January 2018

1 reference

Pharmacokinetics of an Immediate‐Release Oral Formulation of Fampridine (4‐Aminopyridine) in Normal Subjects and Patients with Spinal Cord Injury

21 January 2018

1 reference

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis

21 January 2018

1 reference

Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

Dose comparison trial of sustained-release fampridine in multiple sclerosis

21 January 2018

1 reference

The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.

21 January 2018

1 reference

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1L028

1 reference

30 July 2017

1 reference